NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
FROM THE WIRE · MANILATIMES.NET
Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI studyPhase 3 RESTORE registrational study enrolling participants, with site activation continuing in the United States and Canada…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe FDA designation may draw attention to the stock, although the company is small and in late-stage clinical development.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA granted the designation based on safety and efficacy data from the Phase 1b/2a CONNECT SCI study.
- 02The Phase 3 RESTORE registrational study is enrolling participants.
- 03Site activation is continuing in the United States and Canada.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets